HER2 and COX2 expression in human prostate cancer

被引:72
作者
Edwards, J [1 ]
Mukherjee, R [1 ]
Munro, AF [1 ]
Wells, AC [1 ]
Almushatat, A [1 ]
Bartlett, JMS [1 ]
机构
[1] Univ Glasgow, Glasgow Royal Infirm, Dept Surg,Div Canc Sci & Mol Pathol, Sect Surg & Translat Res,Endocrine Canc Res Grp, Glasgow G31 2ER, Lanark, Scotland
关键词
gene amplification; protein expression;
D O I
10.1016/j.ejca.2003.08.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
COX2 and HER2 expression are associated with a poor prognosis in prostate cancer and HER2 has been linked to COX2 expression in colorectal cancer. The association between COX2 and HER2 expression was investigated in 117 patients with prostate cancer (89) or Benign prostatic hyperplasia (BPH) (28). Tissue was analysed for HER2 amplification by fluorescent in situ hybridisation, and HER2 and COX2 protein expression by immunohistochemistry (IHC). All tumours analysed expressed COX2 at a significantly higher level than BPH tissue (P = 0.041). Only low levels of HER2 gene amplification (8 %, 7/89) and HER2 protein expression (12%, 11/89) were observed. HER2 protein expression was rarely observed and did not correlate with HER2 amplification or COX2 expression. Although HER2 does not drive COX2 expression in prostate cancer, this study identified high levels of COX2 expressed in locally advanced prostate cancer, suggesting COX2 could be a potential therapeutic target. COX2 inhibitors are currently being used in clinical trials for the treatment of other tumour types. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:50 / 55
页数:6
相关论文
共 41 条
[1]   Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents [J].
Agarwal, R .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1051-1059
[2]  
Agus DB, 1999, CANCER RES, V59, P4761
[3]   Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): Inhibition of cyclooxygenase and induction of NSAID-activated gene [J].
Baek, SJ ;
Wilson, LC ;
Lee, CH ;
Eling, TE .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (03) :1126-1131
[4]   COX-2 and cancer: a new approach to an old problem [J].
Bakhle, YS .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (06) :1137-1150
[5]   Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? [J].
Bartlett, JMS ;
Watters, AD ;
Ballantyne, SA ;
Going, JJ ;
Grigor, KM ;
Cooke, TG .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2193-2198
[6]   Evaluating HER2 amplification and overexpression in breast cancer [J].
Bartlett, JMS ;
Going, JJ ;
Mallon, EA ;
Watters, AD ;
Reeves, JR ;
Stanton, P ;
Richmond, J ;
Donald, B ;
Ferrier, R ;
Cooke, TG .
JOURNAL OF PATHOLOGY, 2001, 195 (04) :422-428
[7]  
Bubendorf L, 1999, CANCER RES, V59, P803
[8]   Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells [J].
Coffey, RJ ;
Hawkey, CJ ;
Damstrup, L ;
GravesDeal, R ;
Daniel, VC ;
Dempsey, PJ ;
Chinery, R ;
Kirkland, SC ;
DuBois, RN ;
Jetton, TL ;
Morrow, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) :657-662
[9]   A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [J].
Craft, N ;
Shostak, Y ;
Carey, M ;
Sawyers, CL .
NATURE MEDICINE, 1999, 5 (03) :280-285
[10]   Basic science aspects of prostate cancer [J].
Dorkin, TJ ;
Neal, DE .
SEMINARS IN CANCER BIOLOGY, 1997, 8 (01) :21-27